Multiple sclerosis patients with severe walking disability have clinically meaningful improvements in walking speed with prolonged-release fampridine

被引：0
|
作者：
Hartung, H. P.
Goodman, A.
Putzki, N.
机构：
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [1] Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis
    Mathiesen, Henrik K.
    Sorensen, Per S.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 1309 - 1317
  • [2] Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial
    Hobart, Jeremy
    Ziemssen, Tjalf
    Feys, Peter
    Linnebank, Michael
    Goodman, Andrew
    Farrell, Rachel
    Englishby, Veronica
    McNeill, Manjit
    Chang, Ih
    Mehta, Lahar
    Elkins, Jacob
    NEUROLOGY, 2017, 88
  • [3] Multiple sclerosis patients concurrently treated with disease-modifying therapies show clinically meaningful increases in walking speed with prolonged-release fampridine
    Kieseier, B.
    Schapiro, R.
    Goodman, A.
    Putzki, N.
    JOURNAL OF NEUROLOGY, 2011, 258 : 261 - 261
  • [4] Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability
    Kim, Esther S.
    DRUGS, 2017, 77 (14) : 1593 - 1602
  • [5] Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability
    Esther S. Kim
    Drugs, 2017, 77 : 1593 - 1602
  • [6] Data from prolonged-release fampridine trials confirm that 20% improvement in walking speed is clinically meaningful
    Limmroth, V.
    Putzki, N.
    Goodman, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S244 - S244
  • [7] Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
    Sola-Valls, Nuria
    Blanco, Yolanda
    Sepulveda, Maria
    Llufriu, Sara
    Martinez-Lapiscina, Elena H.
    Zubizarreta, Irati
    Pulido-Valdeolivas, Irene
    Montejo, Carmen
    Villoslada, Pablo
    Saiz, Albert
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [8] BUDGET IMPACT OF ORAL PROLONGED-RELEASE FAMPRIDINE FOR MANAGEMENT OF WALKING DISABILITY ASSOCIATED WITH MULTIPLE SCLEROSIS IN TAIWAN
    Lee-Grossman, C. W.
    Alexopoulos, S. T.
    Murphy, D. R.
    VALUE IN HEALTH, 2012, 15 (07) : A675 - A676
  • [9] Cost-effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China
    Zhao, Xinran
    Yang, Han
    Wei, Tian
    Zhao, Jin
    Liu, Jun
    Huang, Zhe
    Zhu, Lin
    Zhao, Yinan
    Li, Wei
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1057 - 1069
  • [10] Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
    Zoerner, Bjoern
    Filli, Linard
    Reuter, Katja
    Kapitza, Sandra
    Loerincz, Lilla
    Sutter, Tabea
    Weller, David
    Farkas, Melinda
    Easthope, Christopher S.
    Czaplinski, Adam
    Weller, Michael
    Linnebank, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (11) : 1463 - 1475
12345